Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Cancer - 1 Feb 2006

Tefferi Ayalew, Lasho Terra L, Schwager Susan M, Strand Jacob S, Elliott Michelle, Mesa Ruben, Li Chin-Yang, Wadleigh Martha, Lee Stephanie J, Gilliland D Gary

Abstract excerpt

BACKGROUND: Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS: In a single institutional study, mutation screening for JAK2(V617F) was performed in DNA derived from archived blood granulocytes from 63 consecutive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GPI-Linked Proteins
Share to Granulocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemoglobins

Share to Isoantigens

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Protein-Tyrosine Kinases

Share to Pruritus

Source

Identifiers

PMID: 16369984
DOI: 10.1002/cncr.21645

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.PMID 16369984Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.Semantic proximity Read ↗

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.Semantic proximity Read ↗

JAK2 V617F allele burden in polycythemia vera: burden of proof.Semantic proximity Read ↗

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Semantic proximity Read ↗

Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Polycythaemia vera: molecular genetics, diagnostics and therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.